Article
Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target NaV1.7.
Biochemical pharmacology - 1 Nov 2020
Rupasinghe Darshani B, Herzig Volker, Vetter Irina, Dekan Zoltan, Gilchrist John, Bosmans Frank, Alewood Paul F, Lewis Richard J, King Glenn F
Abstract excerpt
Management of chronic pain presents a major challenge, since many currently available treatments lack efficacy and have problems such as addiction and tolerance. Loss of function mutations in the SCN9A gene lead to a congenital inability to feel pain, with no other sensory deficits aside from anosmia. SCN9A encodes the voltage-gated sodium (NaV) channel 1.7 (NaV1.7), which has been identified as a primary pain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.